Message #71 From:
NewsBot Date: November 10, 2006 09:48:00 AM
NYMX News Statin Drugs Gain Traction as Potential Treatment for Alzheimer's Disease
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Statins, the widely used cholesterol drugs with a global market over $25
billion, are gaining wide attention as a potential new way of treating
Alzheimer’s disease (AD) according to recent
reports. The Wall Street Journal noted the promise of statins for
Alzheimer’s disease and highlighted the
pressing need for new and effective treatments for this major disease
(October 17, 2006 Several Drugs Show Promise For Alzheimer's). A
series of recent scientific studies have explored the link between
Alzheimer’s disease, cognitive function and
high cholesterol levels and other cardiovascular risk factors, and the
possible role that statins may have in treating or preventing Alzheimer’s
disease.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global
patent rights for the use of statin drugs for the prevention and
treatment of AD, including for patients at risk for AD because of
vascular-related risk factors or disease.
Statins are widely available cholesterol-lowering drugs with a
well-established track record of safety and are the biggest-selling
prescription pills in pharmaceutical history with estimated 2004 global
sales of $26 billion.
November is National Alzheimer's Disease Awareness Month and also the 100th
anniversary of the first report of Dr. Alois Alzheimer characterizing
the hallmarks of the disease. Alzheimer's disease is the leading cause
of dementia in the elderly, afflicting an estimated 4.5 million people
in the U.S. and 15 million worldwide.
Some of the recent scientific studies and reviews concerning the
potential for statin drugs to treat or reduce the risk of AD or loss of
cognitive function include Neurol Res. 2006; 28:630-6, Acta
Neurol Scand 2006; 114 (Suppl. 185): 78-86, Acta Neurol
Scand 2006; 114 (Suppl. 185): 3–7, J.Neurochem.
2006; 97:716-723; Restor. Neurol. Neurosci 2006; 24:79-95; Neuromolecular
Med. 2006; 8:319-328, Neurology 2005; 65:1388-1394, J.
Neurol. Neurosurg. Psychiatry 2005; 76:1624-1629, The American
Journal of Medicine 2005; 118: 48S-53S; The Lancet Neurology
2005; 4:841-852; Current Opinions in Lipidology 2005;16: 619-623; The
Lancet Neurology 2005; 4: 521-2, Arch Neurol 2005;
62:1047-51, Neurology 2005; 64:1531-8, Arch Neurol 2005;
62:753-7, J Neurol Sci 2005; 229-230:147-50, and Arch Gen
Psychiatry 2005; 62:217-24.
This press release contains certain “forward-looking
statements” as defined in the United States
Private Securities Litigation Reform Act of 1995 that involve a number
of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future
events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
